Megan Kurz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Megan Kurz has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Sander Greenland
Department of Epidemiology and Department of Statistics The University of California, Los Angeles Los Angeles California USA
3 shared publications- Bohdan Nosyk
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada
2 shared publications Jeong Eun Min
Centre for Advancing Health Outcomes Vancouver British Columbia Canada
2 shared publicationsLawrence McCandless
Faculty of Health Sciences Simon Fraser University Burnaby British Columbia Canada
2 shared publicationsMohammad Ehsanul Karim
Centre for Advancing Health Outcomes Vancouver British Columbia Canada
2 shared publicationsPaul Gustafson
Department of Statistics University of British Columbia Vancouver British Columbia Canada
2 shared publications
Latest Publications
- Open Access
Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020
Background and aims: Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment. Current clinical practice guidelines offer relatively limited guidance or evidence on the appropriate timing to initiate a taper. We aimed to determine the safety and comparative effectiveness of different times from completion of OAT induction at which tapering could be considered to maximize the likelihood of taper completion and minimize the risk of mortality. Design: Population‐based retrospective observational study and target trial emulation based on nine linked administrative health databases. Setting: British Columbia, Canada, from 1 January 2010 to 17 March 2020. Participants: Individuals (identified via linkage of nine provincial health administrative databases) completing OAT induction with methadone or buprenorphine/naloxone who were ≥18 years of age with no known pregnancy, no history of cancer or palliative care and not currently incarcerated. We executed both incident‐user (no OAT experiences) and prevalent‐new‐user (no OAT within the past month) analyses. Intervention and comparator: The time between completed OAT induction and taper initiation: <3 months, 3–6 months, 6–12 months, compared with 12–48 months. Measurements: The primary outcomes were completed taper (reaching a final daily dose of ≤5 mg/day for methadone, or ≤2 mg/0.5 mg/day for buprenorphine/naloxone) and all‐cause mortality. A clone‐censor‐weight approach was used to adjust for informative censoring and balance baseline characteristics between the groups. Logistic regression and pooled logistic regression models were used to estimate odds ratios (ORs) for completed taper and hazard ratios (HRs) for all‐cause mortality, respectively, each with 95% compatibility (‘confidence’) intervals. Findings: We included 17 726 incident users (buprenorphine/naloxone: 36.9%) and 49 515 treatment episodes (buprenorphine/naloxone: 31.2%) from 31 231 prevalent new users who completed induction in the analyses. Among prevalent new users, beginning tapering within 3 months, between 3 and 6 months and between 6 and 12 months of completing induction was associated with an increased likelihood of completed taper [methadone: <3 months: adjusted odds ratio (aOR) = 3.09, 95% compatibility interval (95% CI) = 2.58–3.68; buprenorphine/naloxone: <3 months: aOR = 6.90, 95% CI = 5.19–9.16] but a higher risk of mortality [methadone: <3 months: adjusted hazard ratio (aHR) = 1.18, 95% CI = 1.12–1.25; buprenorphine/naloxone: <3 months: aHR = 1.12, 95% CI = 1.05–1.19], compared with initiating a taper between 12 and 48 months. Similar results were found among incident users. Conclusions: Although initiating early tapering off opioid agonist treatment may be associated with a greater likelihood of taper completion, this practice also increases the risk of mortality.
Open AccessComparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020
Background and aims: Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment. Current clinical practice guidelines offer relatively limited guidance or evidence on the appropriate timing to initiate a taper. We aimed to determine the safety and comparative effectiveness of different times from completion of OAT induction at which tapering could be considered to maximize the likelihood of taper completion and minimize the risk of mortality. Design: Population‐based retrospective observational study and target trial emulation based on nine linked administrative health databases. Setting: British Columbia, Canada, from 1 January 2010 to 17 March 2020. Participants: Individuals (identified via linkage of nine provincial health administrative databases) completing OAT induction with methadone or buprenorphine/naloxone who were ≥18 years of age with no known pregnancy, no history of cancer or palliative care and not currently incarcerated. We executed both incident‐user (no OAT experiences) and prevalent‐new‐user (no OAT within the past month) analyses. Intervention and comparator: The time between completed OAT induction and taper initiation: <3 months, 3–6 months, 6–12 months, compared with 12–48 months. Measurements: The primary outcomes were completed taper (reaching a final daily dose of ≤5 mg/day for methadone, or ≤2 mg/0.5 mg/day for buprenorphine/naloxone) and all‐cause mortality. A clone‐censor‐weight approach was used to adjust for informative censoring and balance baseline characteristics between the groups. Logistic regression and pooled logistic regression models were used to estimate odds ratios (ORs) for completed taper and hazard ratios (HRs) for all‐cause mortality, respectively, each with 95% compatibility (‘confidence’) intervals. Findings: We included 17 726 incident users (buprenorphine/naloxone: 36.9%) and 49 515 treatment episodes (buprenorphine/naloxone: 31.2%) from 31 231 prevalent new users who completed induction in the analyses. Among prevalent new users, beginning tapering within 3 months, between 3 and 6 months and between 6 and 12 months of completing induction was associated with an increased likelihood of completed taper [methadone: <3 months: adjusted odds ratio (aOR) = 3.09, 95% compatibility interval (95% CI) = 2.58–3.68; buprenorphine/naloxone: <3 months: aOR = 6.90, 95% CI = 5.19–9.16] but a higher risk of mortality [methadone: <3 months: adjusted hazard ratio (aHR) = 1.18, 95% CI = 1.12–1.25; buprenorphine/naloxone: <3 months: aHR = 1.12, 95% CI = 1.05–1.19], compared with initiating a taper between 12 and 48 months. Similar results were found among incident users. Conclusions: Although initiating early tapering off opioid agonist treatment may be associated with a greater likelihood of taper completion, this practice also increases the risk of mortality.
- Open Access
Comparative effectiveness of take-home dosing schedules for opioid agonist treatment in British Columbia, Canada: a target trial emulation protocol using a population-based observational study
Introduction The introduction of fentanyl and its analogues in the illicit drug supply has prompted greater emphasis on refining clinical treatment protocols to ensure sustained retention in opioid agonist treatment (OAT). Take-home dosing may lessen the treatment burden on clients and thus reduce the risk of treatment discontinuation. The evidence base supporting the use of take-home dosing, including the optimal duration of dispensations, is, however, limited. The objective of this study is to determine the comparative effectiveness of alternative take-home dosing schedules, as observed in clinical practice in British Columbia, Canada from 2010 to 2022. Methods and analysis We propose to emulate a target trial with a population-level retrospective study of individuals initiating methadone or buprenorphine/naloxone between 1 January 2010 and 31 December 2022 who are 18 years of age or older and not currently incarcerated or pregnant with no history of cancer or palliative care. Our study will draw on nine linked health administrative databases from British Columbia and will evaluate take-home doses of 2–5 days, 6 days or >6 days compared with continuous daily dosing. The primary outcomes include OAT discontinuation and all-cause mortality on treatment. A causal per-protocol analysis is proposed with longitudinal matching and inverse probability of censoring weighting approaches to adjust for time-fixed and time-varying confounding. A range of sensitivity analyses will be executed to determine the robustness of results. Ethics and dissemination The protocol, cohort creation and analysis plan have been classified and approved as a quality improvement initiative by Providence Health Care Research Ethics Board and the Simon Fraser University Office of Research Ethics. Results will be disseminated and shared with local advocacy groups and decision-makers, developers of national and international clinical guidelines, presented at national and international conferences and published in peer-reviewed journals electronically and in print.
Open AccessComparative effectiveness of take-home dosing schedules for opioid agonist treatment in British Columbia, Canada: a target trial emulation protocol using a population-based observational study
Introduction The introduction of fentanyl and its analogues in the illicit drug supply has prompted greater emphasis on refining clinical treatment protocols to ensure sustained retention in opioid agonist treatment (OAT). Take-home dosing may lessen the treatment burden on clients and thus reduce the risk of treatment discontinuation. The evidence base supporting the use of take-home dosing, including the optimal duration of dispensations, is, however, limited. The objective of this study is to determine the comparative effectiveness of alternative take-home dosing schedules, as observed in clinical practice in British Columbia, Canada from 2010 to 2022. Methods and analysis We propose to emulate a target trial with a population-level retrospective study of individuals initiating methadone or buprenorphine/naloxone between 1 January 2010 and 31 December 2022 who are 18 years of age or older and not currently incarcerated or pregnant with no history of cancer or palliative care. Our study will draw on nine linked health administrative databases from British Columbia and will evaluate take-home doses of 2–5 days, 6 days or >6 days compared with continuous daily dosing. The primary outcomes include OAT discontinuation and all-cause mortality on treatment. A causal per-protocol analysis is proposed with longitudinal matching and inverse probability of censoring weighting approaches to adjust for time-fixed and time-varying confounding. A range of sensitivity analyses will be executed to determine the robustness of results. Ethics and dissemination The protocol, cohort creation and analysis plan have been classified and approved as a quality improvement initiative by Providence Health Care Research Ethics Board and the Simon Fraser University Office of Research Ethics. Results will be disseminated and shared with local advocacy groups and decision-makers, developers of national and international clinical guidelines, presented at national and international conferences and published in peer-reviewed journals electronically and in print.
- Open Access
Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population‐based target trial in British Columbia, Canada
Background and aim: Urine drug testing is often utilized alongside opioid agonist treatment to assess client progress by validating self‐reported substance use, monitoring for diversion and supporting clinical decisions for take‐home dosing. However, there is a paucity of evidence to support the practice of urine drug testing. We aimed to determine the association of alternative urine drug testing frequencies with opioid agonist treatment discontinuation, compared with no monitoring, among individuals receiving methadone or buprenorphine/naloxone treatment. Design: Population‐based retrospective cohort study and target trial emulation based on nine‐linked administrative databases. Setting: British Columbia, Canada, between 1 January 2010 and 17 March 2020. Participants: Individuals with no history of cancer or palliative care, aged 18 or older and no indication of pregnancy who initiated methadone or buprenorphine/naloxone. A total of 18 988 methadone and 11 910 buprenorphine/naloxone recipients were included in the incident user design (individuals with no past opioid agonist treatment experience). Measurements: We used a clone‐censor‐weight approach to estimate hazard ratios with 95% compatibility (“confidence”) intervals for treatment discontinuation (lasting at least 5 and 6 days for methadone and buprenorphine, respectively) and all‐cause mortality on treatment within 12 months for static urine drug testing strategies. Findings: Under static monitoring strategies, weekly urine drug testing was associated with a slightly reduced risk of discontinuation in the first year of continuous retention in treatment [methadone: adjusted hazard ratio (aHR) = 0.96, 95% compatibility interval (CI) = (0.95–0.98); buprenorphine/naloxone: aHR = 0.95 (0.94–0.97)] compared with no monitoring. The estimated associations of weekly urine drug testing with all‐cause mortality were similar in size but extremely imprecise [methadone: aHR = 0.95 (0.78–1.15), buprenorphine/naloxone: aHR = 0.99 (0.62–1.58)]. Less frequent testing demonstrated no observed difference on treatment discontinuation or all‐cause mortality compared with no monitoring. Conclusion: Compared with no urine drug testing, weekly urine drug testing may be associated with improved opioid agonist treatment retention; however, the high costs attributable to frequent testing may not be cost‐effective and requires further evaluation. There was no improvement associated with less frequent testing compared with no monitoring.
Open AccessComparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population‐based target trial in British Columbia, Canada
Background and aim: Urine drug testing is often utilized alongside opioid agonist treatment to assess client progress by validating self‐reported substance use, monitoring for diversion and supporting clinical decisions for take‐home dosing. However, there is a paucity of evidence to support the practice of urine drug testing. We aimed to determine the association of alternative urine drug testing frequencies with opioid agonist treatment discontinuation, compared with no monitoring, among individuals receiving methadone or buprenorphine/naloxone treatment. Design: Population‐based retrospective cohort study and target trial emulation based on nine‐linked administrative databases. Setting: British Columbia, Canada, between 1 January 2010 and 17 March 2020. Participants: Individuals with no history of cancer or palliative care, aged 18 or older and no indication of pregnancy who initiated methadone or buprenorphine/naloxone. A total of 18 988 methadone and 11 910 buprenorphine/naloxone recipients were included in the incident user design (individuals with no past opioid agonist treatment experience). Measurements: We used a clone‐censor‐weight approach to estimate hazard ratios with 95% compatibility (“confidence”) intervals for treatment discontinuation (lasting at least 5 and 6 days for methadone and buprenorphine, respectively) and all‐cause mortality on treatment within 12 months for static urine drug testing strategies. Findings: Under static monitoring strategies, weekly urine drug testing was associated with a slightly reduced risk of discontinuation in the first year of continuous retention in treatment [methadone: adjusted hazard ratio (aHR) = 0.96, 95% compatibility interval (CI) = (0.95–0.98); buprenorphine/naloxone: aHR = 0.95 (0.94–0.97)] compared with no monitoring. The estimated associations of weekly urine drug testing with all‐cause mortality were similar in size but extremely imprecise [methadone: aHR = 0.95 (0.78–1.15), buprenorphine/naloxone: aHR = 0.99 (0.62–1.58)]. Less frequent testing demonstrated no observed difference on treatment discontinuation or all‐cause mortality compared with no monitoring. Conclusion: Compared with no urine drug testing, weekly urine drug testing may be associated with improved opioid agonist treatment retention; however, the high costs attributable to frequent testing may not be cost‐effective and requires further evaluation. There was no improvement associated with less frequent testing compared with no monitoring.